I Read Every Retatrutide Trial So You Don't Have To

Summary

Dr. Mike reviews retatrutide’s proposed benefits, clinical-trial results, side effects, approval status, and risks associated with products sold online. His central message is that the drug appears highly effective in clinical trials, but it is not approved for general use, and online products may be mislabeled or contaminated.

What retatrutide is

• The presenter describes retatrutide as a “triple” receptor agonist that acts on GLP-1, GIP, and glucagon receptors.
• He contrasts it with semaglutide, which acts on GLP-1 receptors, and tirzepatide, which acts on GLP-1 and GIP receptors.
• He says the glucagon action may increase the body’s use of stored fuel in addition to reducing appetite. This is the presenter’s simplified explanation of the drug’s mechanism.

Trial results discussed

The video discusses the TRIUMPH-1 trial, which involved 2,339 adults with obesity who did not have diabetes. Participants received weekly injections for 80 weeks, and results were compared with placebo.

The presenter reports average weight loss of about 28.3% at the highest dose. He estimates that a more realistic figure may be closer to 25% after accounting for missed doses and people who left the trial. He gives the following dose-related results:

• 4 mg weekly: 17.6% average weight loss
• 9 mg weekly: 23.7%
• 12 mg weekly: About 25% in his adjusted estimate

He reports 4% weight loss in the placebo group and compares retatrutide’s results with figures of 15% for semaglutide and 21% for tirzepatide.

His conclusion is that retatrutide appears especially effective, while emphasizing that the headline result should be considered alongside side effects and other limitations.

Side effects highlighted

• Nausea: 29–42%, depending on dose. The presenter notes that 15% of placebo participants also reported nausea.
• Vomiting: About 11–25%.
• Diarrhea: About 33%.

He says these gastrointestinal effects appear more common with retatrutide than with similar drugs. He also highlights dysesthesia—unusual skin sensations such as tingling, burning, or a crawling feeling—which was reported in roughly 5–12% of participants. He describes it as a notable effect not previously seen with similar medications.

The presenter says side effects may lead many people to stop treatment and argues that gradual dose increases may be used if the drug is approved.

Approval and online-product risks

The video says retatrutide was not approved for general use anywhere at the time discussed. The presenter says Eli Lilly planned to submit an application to the US FDA in early 2027, with approval potentially later in 2027 or in 2028, and potentially later in Australia and the UK.

He warns that products sold online are unlicensed and may not contain what their labels claim. He cites:

• A University of Queensland test of 18 online vials, in which only one reportedly matched its label. Some contained more or less active ingredient than stated, and one was empty.
• A US test of 6,000 bottles from 200 sellers, in which four in ten reportedly failed basic manufacturing standards and 15% contained endotoxins.

The video also mentions reports of allergic reactions, Eli Lilly legal action against sellers, a warning from Australia’s TGA, and an MHRA raid on a UK facility producing counterfeit pens.

The presenter acknowledges why people may seek the drug online but stresses that the contents and dose may be unpredictable.

Precautions recommended by the presenter

The presenter advises people considering or already using retatrutide to:

• Speak with a doctor and disclose use, including use of an online product.
• Discuss baseline checks such as kidney and liver function, HbA1c, thyroid function, blood count, blood pressure, and heart rate.
• Consider an eye examination, which he also recommends for people starting other weight-loss drugs.
• Avoid rapid dose increases. He describes gradual titration over months as the likely approach if the drug is approved.
• Seek medical advice if they experience unusual skin sensations or itching, dizziness on standing, prolonged constipation, or nausea severe enough to prevent eating.

These are the presenter’s suggestions, not a substitute for individualized medical care. The video’s overall caution is that trial results for the molecule do not establish the safety or quality of unregulated products sold online.

Speakers and sources mentioned

• Dr. Mike — The video’s presenter and narrator; the only speaking voice identified in the subtitles.
• TRIUMPH-1 — The clinical trial discussed for weight-loss results.
• University of Queensland researchers — Cited for testing 18 online vials.
• An unnamed US study — Cited for testing 6,000 bottles from 200 sellers.
• Eli Lilly — Identified as the manufacturer and as having pursued legal action against sellers.
• Australia’s TGA — Cited as issuing a warning.
• The UK MHRA — Cited in connection with a raid on a counterfeit-product facility.
• Semaglutide and tirzepatide trial results — Used as comparisons; specific studies are not named in the subtitles.